Skip to main content
. Author manuscript; available in PMC: 2017 Nov 8.
Published in final edited form as: Clin Pharmacokinet. 2015 Feb;54(2):147–166. doi: 10.1007/s40262-014-0230-6

Figure 2.

Figure 2

Prevalence of patients with high on-treatment platelet reactivity (HPR) according to age, body mass index and diabetes mellitus status. HPR was defined as residual platelet aggregation (RPA) > 14%, which was assessed by light transmittance aggregometry (LTA) assay with ADP 5 μmol/L following a 600 mg of clopidogrel loading dose in 760 patients undergoing elective coronary stent implantation [41].